CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

3 months ago 10
Read Entire Article
  1. Homepage
  2. Finance
  3. CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

Related

UBS lowers Hess Midstream stock price target to $34 on Bakken rig reduction

UBS lowers Hess Midstream stock price target to $34 on Bakke...

36 minutes ago 0
Factbox-From OpenAI to Meta, firms channel billions into AI infrastructure as demand booms

Factbox-From OpenAI to Meta, firms channel billions into AI ...

36 minutes ago 0
Permian Resources stock rating reiterated at Buy by UBS ahead of earnings

Permian Resources stock rating reiterated at Buy by UBS ahea...

36 minutes ago 0

Trending

1. sherri shepherd
2. howard marks
3. rigetti stock
4. rgti
5. qs stock
6. ibm stock
7. vz stock
8. nasdaq today
9. oklo stock
10. dow jones

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

8 months ago 580
What is Tren de Aragua, the Venezuelan gang targeted by Trump?

What is Tren de Aragua, the Venezuelan gang targeted by Trum...

6 months ago 367
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

9 months ago 262
Taiwan slightly cuts 2025 GDP growth outlook amid Trump tariffs concern

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

7 months ago 252
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

7 months ago 225
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2025. All rights are reserved